Physician profile
Abigail Rotberg
NPI 1952046203
$3,223.18
in general payments reported to CMS, 2019-2025
16 companies · $668 in 2025
The $668 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $31.76 · 2023: $1,352 · 2024: $1,172 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,143 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,142.58 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $617.82 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $442.29 | 2023-2024 | Jornay Pm |
| Abbvie INC. | $390.95 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $353.84 | 2022-2024 | Caplyta |
| Axsome Therapeutics, INC. | $231.82 | 2023-2025 | Auvelity |
| Neos Therapeutics, Lp | $207.80 | 2023-2025 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $202.52 | 2025 | Jornay Pm |
| Alkermes, INC. | $160.23 | 2023-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $145.31 | 2023-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $122.32 | 2022-2025 | Rexulti |
| Vertical Pharmaceuticals, LLC | $80.05 | 2024-2025 | Relexxii |
| Almatica Pharma LLC | $71.38 | 2023 | Sertraline Hcl, Loreev Xr |
| Supernus Pharmaceuticals, INC. | $64.62 | 2023 | Qelbree |
| Tris Pharma INC | $56.08 | 2023-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $52.57 | 2024-2025 | Uzedy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $23.58 | 2024 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Rotberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.